Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN, USA.
J Vasc Surg. 2011 Jan;53(1):99-106, 107.e1-7; discussion 106-7. doi: 10.1016/j.jvs.2010.08.018.
We previously reported that in situ rifampin-soaked grafts (ISRGs) were safe in select patients with aortic graft infections, with the best results in those with aortic graft enteric erosion or fistula (AGEF). This study evaluates the late results of ISRG for AGEF.
From 1990 to 2008, 183 patients were treated for aortic graft infections (121 primary and 62 AGEF). We reviewed 54 patients treated for AGEF with a standard protocol, which included excision of the infected part of the graft, intestinal repair, ISRG with omental wrap, and long-term antibiotics. We excluded 8 patients with AGEF (13%) treated with axillofemoral grafts (AXFG, n = 5) or in situ femoral vein (n = 3) due to excessive perigraft purulence. Endpoints were early morbidity and mortality, late survival, reinfection, and graft-related complications.
There were 45 male patients and 9 female patients with a mean age of 69 ± 9 years. Presentation was gastrointestinal bleeding in 33 patients, fever in 25 patients, and hemorrhagic shock in 10 patients. Other features were perigraft fluid in 29 patients and purulence in 9 patients. Forty-two patients (80%) had infections isolated to a portion of the graft body or limb, with the remainder of the graft well incorporated. Total graft excision was performed in 31 patients and partial excision in 23 patients. Total operating time was 6.2 ± 1.9 hours. Postoperative complications occurred in 28 patients (52%), and there were 5 deaths (9%). Operative mortality was 2.3% in stable patients (1 of 44) and 40% in those with hemorrhagic shock (4 of 10; P < .001). The hospital stay was 20 ± 18 days. Mean follow-up was 51 months (range, 3-197 months). Five-year patient survival, primary graft patency, and limb salvage rates were 59 ± 8%, 92 ± 5%, and 100%, respectively. There were no late graft-related deaths. There were two (4%) graft reinfections, one that was treated with axillofemoral bypass, and the other with perigraft fluid aspiration and oral antibiotic suppression.
ISRGs with omental wrap and long-term antibiotics are associated with low reinfection rates in patients with AGEF who do not have excessive perigraft purulence. Graft patency and limb salvage rates are excellent.
我们之前曾报道过,在选择患有主动脉移植物感染的患者中,局部利福平浸涂移植物(ISRG)是安全的,对于有主动脉移植物肠侵蚀或瘘管(AGEF)的患者效果最好。本研究评估了 ISRG 治疗 AGEF 的晚期结果。
1990 年至 2008 年,183 例患者因主动脉移植物感染接受治疗(原发性 121 例,AGEF 62 例)。我们回顾了 54 例 AGEF 患者的标准治疗方案,其中包括切除感染的移植物部分、肠修复、带网膜包裹的 ISRG 和长期抗生素治疗。我们排除了 8 例 AGEF(13%)患者,这些患者因移植周围大量脓性分泌物而接受腋股移植物(AXFG,n=5)或原位股静脉(n=3)治疗。主要终点是早期发病率和死亡率、晚期生存率、再感染和移植物相关并发症。
45 例男性患者和 9 例女性患者,平均年龄 69±9 岁。临床表现为 33 例胃肠道出血、25 例发热和 10 例出血性休克。其他特征包括 29 例移植周围积液和 9 例脓性分泌物。42 例(80%)感染局限于移植物体或肢体的一部分,其余部分移植物已完全融合。31 例患者行全段移植物切除术,23 例患者行部分切除术。总手术时间为 6.2±1.9 小时。28 例(52%)患者术后发生并发症,死亡 5 例(9%)。稳定患者的手术死亡率为 2.3%(44 例中的 1 例),出血性休克患者的手术死亡率为 40%(10 例中的 4 例;P<0.001)。住院时间为 20±18 天。平均随访时间为 51 个月(范围 3-197 个月)。5 年患者生存率、移植物一期通畅率和肢体存活率分别为 59±8%、92±5%和 100%。无晚期移植物相关死亡。有 2 例(4%)移植物再感染,1 例经腋股旁路治疗,1 例经移植周围积液抽吸和口服抗生素抑制治疗。
对于没有大量移植周围脓性分泌物的 AGEF 患者,带网膜包裹的 ISRG 和长期抗生素治疗可降低再感染率,同时保持较高的移植物通畅率和肢体存活率。